Rusfertide has received orphan drug, fast track, and breakthrough therapy designations from the FDA, and in this interview, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the critical need ...

Ruxolitinib improves hematocrit control and treatment response in polycythemia vera compared to best available therapy. Patients on ruxolitinib show better Myeloproliferative Neoplasms-Symptom ...

Rusfertide significantly improves hematocrit control and reduces the mean number of phlebotomies in patients who are phlebotomy-dependent despite standard care. The Food and Drug Administration (FDA) ...

Learn about Polycythemia Vera, a rare blood disorder, its symptoms, risk factors, complications, and how early diagnosis and ...

A breakthrough in the treatment of polycythemia vera, a rare and life-threatening blood cancer, has emerged with the introduction of a new drug named rusfertide. Polycythemia vera falls under the ...

CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for phlebotomy among polycythemia vera patients who had been dependent on it, the ...

Rusfertide showed a 77% clinical response rate in polycythemia vera patients, significantly higher than the 33% with placebo. The drug reduced phlebotomy frequency, with 0.5 per patient in the ...

Findings showed 77% of PV patients treated with rusfertide achieved a clinical response compared with 33% of those who received placebo. Topline data were announced from a phase 3 trial evaluating ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — First-line treatment with ruxolitinib led to “clinically meaningful” positive results versus best ...

A panelist discusses how patients should communicate comprehensively with their care team about symptom patterns, documentation methods, and warning signs of polycythemia vera progression, including ...

Breakthrough designation for rusfertide was supported by positive 32-week data from the Phase 3 VERIFY study, which was presented as a late breaking abstract highlighting its practice-changing ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: My husband (age 71) received a diagnosis of polycythemia ...